Assignee profile:

Alkermes, Inc.

City:

Waltham, Massachusetts

Country:

United States

Published Applications:

62

Last publication date:

2024-05-30

Patent Grants:

51

Last grant date:

2026-05-26

Top Inventors for applications by Alkermes, Inc.

These are the the leading inventors for applications assigned to Alkermes, Inc.:

Recent patent applications by Alkermes, Inc.

Alkermes, Inc. based in Waltham, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2024-05-30 ✅ Patent 12,637,476 granted on 2026-05-26
US20240174689A1
Chemistry; metallurgy

SUBSTITUTED CARBAMATE MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT

#2 | 2024-03-07 ✅ Patent 12,441,710 granted on 2025-10-14
US20240076283A1
Chemistry; metallurgy

Substituted Piperidino Compounds and Related Methods of Treatment

#3 | 2023-10-26 ✅ Patent 12,054,495 granted on 2024-08-06
US20230339969A1
Chemistry; metallurgy

Substituted macrocyclic compounds and related methods of treatment

#4 | 2022-10-27 ✅ Patent 11,987,580 granted on 2024-05-21
US20220340560A1
Chemistry; metallurgy

Bicyclic inhibitors of histone deacetylase

#5 | 2022-10-27 ✅ Patent 11,912,702 granted on 2024-02-27
US20220340558A1
Chemistry; metallurgy

Substituted pyridines as inhibitors of histone deacetylase

#6 | 2022-06-23 ✅ Patent 12,006,330 granted on 2024-06-11
US20220194958A1
Chemistry; metallurgy

Substituted macrocyclic compounds and related methods of treatment

#7 | 2022-06-23 ✅ Patent 11,760,747 granted on 2023-09-19
US20220194926A1
Chemistry; metallurgy

Substituted piperidino compounds and related methods of treatment

#8 | 2021-09-09 ✅ Patent 11,858,939 granted on 2024-01-02
US20210277007A1
Chemistry; metallurgy

Hetero-halo inhibitors of histone deacetylase

#9 | 2021-08-05
US20210238177A1
Chemistry; metallurgy

CRYSTALLINE FORMS OF 3-((1R,5S,9r)-9-ETHOXY-3-AZABICYCLO[3.3.1]NONAN-9-YL)-BENZAMIDE AND SALT FORMS THEREOF

#10 | 2021-05-27 ✅ Patent 11,542,276 granted on 2023-01-03
US20210155636A1
Chemistry; metallurgy

Substituted macrocyclic compounds and related methods of treatment

#11 | 2021-05-20 ✅ Patent 11,225,475 granted on 2022-01-18
US20210147410A1
Chemistry; metallurgy

Substituted pyridines as inhibitors of histone deacetylase

#12 | 2021-04-29 ✅ Patent 11,225,479 granted on 2022-01-18
US20210122748A1
Chemistry; metallurgy

Bicyclic inhibitors of histone deacetylase

#13 | 2021-02-25 ✅ Patent 11,286,256 granted on 2022-03-29
US20210053964A1
Chemistry; metallurgy

Bicyclic inhibitors of histone deacetylase

#14 | 2020-08-06 ✅ Patent 10,919,902 granted on 2021-02-16
US20200247814A1
Chemistry; metallurgy

Hetero-halo inhibitors of histone deacetylase

#15 | 2019-11-07 ✅ Patent 11,534,480 granted on 2022-12-27
US20190336582A1
Human necessities

Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties

#16 | 2019-08-08 ✅ Patent 10,604,489 granted on 2020-03-31
US20190241524A1
Chemistry; metallurgy

Compounds for the treatment of pain

#17 | 2018-10-11 ✅ Patent 10,881,741 granted on 2021-01-05
US20180289825A1
Human necessities

Single chain Fc fusion proteins

#18 | 2017-12-28 ✅ Patent 10,335,459 granted on 2019-07-02
US20170368144A1
Human necessities

Compositions for modulating IL-10 immunostimulatory and anti-inflammatory properties

#19 | 2017-01-12 ✅ Patent 9,775,840 granted on 2017-10-03
US20170007609A1
Human necessities

Peripherally acting opioid compounds

#20 | 2016-08-18 ✅ Patent 10,183,979 granted on 2019-01-22
US20160237132A1
Chemistry; metallurgy

Fusion polypeptides comprising mucin-domain polypeptide linkers

#21 | 2016-02-25 ✅ Patent 10,023,623 granted on 2018-07-17
US20160052983A1
Chemistry; metallurgy

Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide

#22 | 2015-07-16 ✅ Patent 9,415,045 granted on 2016-08-16
US20150196550A1
Human necessities

Peripherally acting opioid compounds

#23 | 2014-10-09 ✅ Patent 8,975,272 granted on 2015-03-10
US20140303200A1
Chemistry; metallurgy

Polymorphic forms of naltrexone

#24 | 2014-09-18
US20140275109A1
Human necessities

Methods for Administering Aripiprazole

#25 | 2014-08-21 ✅ Patent 9,428,563 granted on 2016-08-30
US20140234962A1
Chemistry; metallurgy

Ligands modified by circular permutation as agonists and antagonists

#26 | 2014-06-05
US20140155424A1
Human necessities

NALTREXONE LONG ACTING FORMULATIONS AND METHODS OF USE

#27 | 2014-01-02 ✅ Patent 9,040,552 granted on 2015-05-26
US20140005215A1
Chemistry; metallurgy

Selective opioid compounds

#28 | 2013-12-19 ✅ Patent 9,156,897 granted on 2015-10-13
US20130338067A1
Chemistry; metallurgy

Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide

#29 | 2013-12-19 ✅ Patent 9,296,801 granted on 2016-03-29
US20130336925A1
Chemistry; metallurgy

Fusion polypeptides comprising mucin-domain polypeptide linkers

#30 | 2013-12-19 ✅ Patent 9,359,415 granted on 2016-06-07
US20130336924A1
Chemistry; metallurgy

Ligands modified by circular permutation as agonists and antagonists

#31 | 2013-09-26 ✅ Patent 8,735,420 granted on 2014-05-27
US20130253199A1
Chemistry; metallurgy

Polymorphic forms of naltrexone

#32 | 2013-04-11 ✅ Patent 8,759,351 granted on 2014-06-24
US20130090343A1
Human necessities

Methods for administering aripiprazole

#33 | 2013-01-03 ✅ Patent 8,962,646 granted on 2015-02-24
US20130005755A1
Human necessities

Peripherally acting opioid compounds

#34 | 2012-11-15 ✅ Patent 8,338,428 granted on 2012-12-25
US20120289516A1
Human necessities

Methods for administering aripiprazole

#35 | 2012-10-11 ✅ Patent 9,029,543 granted on 2015-05-12
US20120258981A1
Chemistry; metallurgy

Process for the synthesis of quaternary amine compounds

#36 | 2012-10-11
US20120258914A1
Human necessities

COACERVATION PROCESS

#37 | 2012-09-20 ✅ Patent 9,034,867 granted on 2015-05-19
US20120238552A1
Human necessities

Pharmaceutical compositions comprising sorbitan esters

#38 | 2012-03-29 ✅ Patent 8,778,960 granted on 2014-07-15
US20120077800A1
Human necessities

Methods for treating antipsychotic-induced weight gain

#39 | 2012-01-19 ✅ Patent 9,107,911 granted on 2015-08-18
US20120015866A1
Chemistry; metallurgy

Prodrugs of heteraromatic compounds

#40 | 2012-01-12
US20120010412A1
Chemistry; metallurgy

Process for the Synthesis of Substituted Morphinans

#41 | 2011-12-29 ✅ Patent 8,592,427 granted on 2013-11-26
US20110319422A1
Human necessities

Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives

#42 | 2011-11-10 ✅ Patent 8,536,328 granted on 2013-09-17
US20110275803A1
Chemistry; metallurgy

Process for synthesizing oxidized lactam compounds

#43 | 2011-09-01
US20110212985A1
Human necessities

Naltrexone Long Acting Formulations and Methods of Use

#44 | 2011-07-21 ✅ Patent 9,670,200 granted on 2017-06-06
US20110178068A1
Chemistry; metallurgy

Quaternary ammonium salt prodrugs

#45 | 2011-07-07
US20110166194A1
Human necessities

Asenapine Prodrugs

#46 | 2011-07-07
US20110166156A1
Chemistry; metallurgy

Prodrugs for the Treatment of Schizophrenia and Bipolar Disease

#47 | 2011-07-07
US20110166128A1
Human necessities

Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders

#48 | 2011-06-23 ✅ Patent 8,404,276 granted on 2013-03-26
US20110151008A1
Human necessities

Pulmonary delivery for levodopa

#49 | 2011-05-26
US20110123574A1
Human necessities

INHALABLE SUSTAINED THERAPEUTIC FORMULATIONS

#50 | 2011-04-14 ✅ Patent 8,187,672 granted on 2012-05-29
US20110086104A1
Human necessities

Residual solvent extraction method and microparticles produced thereby

#51 | 2011-02-01 ✅ Patent 7,879,358 granted on 2011-02-01
US10392342
-

Pulmonary delivery for levodopa

#52 | 2010-09-23
US20100240691A1
Human necessities

MORPHINAN DERIVATIVES WITH HIGH ORAL BIOAVAILABILITY

#53 | 2010-07-13 ✅ Patent 7,754,242 granted on 2010-07-13
US10392333
-

Inhalable sustained therapeutic formulations

#54 | 2010-06-17 ✅ Patent 8,461,105 granted on 2013-06-11
US20100152111A1
Human necessities

Polymer-based sustained release device

#55 | 2010-06-17 ✅ Patent 8,431,685 granted on 2013-04-30
US20100152097A1
Human necessities

Polymer-based sustained release device

#56 | 2010-03-16 ✅ Patent 7,678,364 granted on 2010-03-16
US9822716
-

Particles for inhalation having sustained release properties

#57 | 2009-08-20 ✅ Patent 8,354,534 granted on 2013-01-15
US20090209569A1
Human necessities

Selective opioid compounds

#58 | 2009-08-06 ✅ Patent 7,875,310 granted on 2011-01-25
US20090194894A1
Human necessities

Residual solvent extraction method and microparticles produced thereby

#59 | 2009-06-04 ✅ Patent 8,338,427 granted on 2012-12-25
US20090143403A1
Human necessities

Methods for administering aripiprazole

#60 | 2008-10-02 ✅ Patent 7,807,200 granted on 2010-10-05
US20080241253A1
Human necessities

Formulations for spray-drying large porous particles

#61 | 2008-09-18 ✅ Patent 8,389,540 granted on 2013-03-05
US20080227804A1
Human necessities

Polymorphic forms of naltrexone

#62 | 2005-11-03 ✅ Patent 7,919,499 granted on 2011-04-05
US20050245558A1
Human necessities

Naltrexone long acting formulations and methods of use

Also check out Alkermes, Inc.'s (Waltham, United States) applicant profile with 40 patent applications submitted.

AssigneeID:

17701 ⎘